Starvation Syndrome Daily Inter Lake, MT - Alyvia, 6, has Prader-Willi Syndrome, a genetic disorder that affects the hypothalamus, the part of the brain that controls appetite and satiety. ...
ScientIST: 20th Anniversary of World AIDS Day LAist, CA - 46 minutes ago AIDS, or acquired immune deficiency syndrome, is the final stage of the HIV infection, when a threshold of immune system destruction is reached. ...
Testing for Fragile X Gene Mutations Throughout the Life Span Journal of American Medical Association (subscription), IL - Nov 25, 2008 One of the most exciting advances in the treatment of fragile X syndrome was the discovery that the absence of FMRP leads to enhanced long-term depression ...
World AIDS Day 2008 recap Scientist Live, UK - HIV breakthrough: A Canada-US research team has solved a major genetic mystery: How a protein in some people's DNA guards them against killer immune ...
European Team Combines GWAS and Metabolomics to ID Genetic... GenomeWeb News, NY - Nov 28, 2008 For instance, the team cited potential links between long-chain fatty acid metabolism and attention deficit hyperactivity syndrome, ties between LIPC enzyme ...
Caffeine: Overcomer of Deficits Blogger News Network - Nov 29, 2008 And those who can drink several cups of coffee in the evening before dropping off to sleep like babies might in fact confront a powerful withdrawal syndrome...
Recent News and Articles on the Keywords: new + 270,000 + syndrome Related to the article below (Last Update: 8/7/2008)
CDC, FDA Release Statement Saying HPV Vaccine Gardasil Remains ... Medical News Today (press release), UK - Jul 25, 2008 About 500000 women worldwide develop cervical cancer annually, and about 270000 women die from the disease each year, according to the New Vision . ...
14000 AIDS deaths recorded in Caribbean last year Jamaica Observer, Jamaica - Jul 30, 2008 The figures, which were released as part of the Caribbean Launch of the UNAIDS Global report 2008, showed that last year an estimated 230000 to 270000...
Source: Google News
Risk of Vascular Anomalies With Down Syndrome - AK Greene, S Kim, GF Rogers, SJ Fishman, BR Olsen, … - Pediatrics, 2008 - Am Acad Pediatrics ... this table: [in this window] [in a new window], TABLE ... The 95% CI for 2 patients with
Down syndrome in our population of vascular anomalies was (1/270000 to 1 ...
[CITATION] Immune reconstitution syndrome, a new disease in HIV-infected patients being successfully treated … A Therapie - Dtsch med Wochenschr, 2001
Open reading frame 2 of porcine circovirus type 2 encodes a major capsid protein - P Nawagitgul, I Morozov, SR Bolin, PA Harms, SD … - Journal of General Virology, 2000 - Soc General Microbiol ... with the newly emerged post-weaning multisystemic wasting syndrome (PMWS) of ... in 37%
CsCl in water at 270000 g for ... 63K): [in this window] [in a new window], Fig. ...
New Injectors and HIV-1 Risk - SR Friedman, P Friedmann, P Telles, F Bastos, R … - Drug Injecting and HIV Infection - books.google.com Chapter 5 New Injectors and HIV-1 Risk Samuel R. Friedman, Patricia Friedmann, Paulo
Telles, Francisco Bastos, Regina Bueno, Fabio Mesquita and Don C. Des ...
New approach for genetic screening for long QT syndrome
Italian researchers have developed a novel approach for genetic screening for long QT syndrome ( LQTS ), an inherited disease that predisposes young individuals to cardiac arrhythmias and sudden death.
The clinical value of genetic testing has been demonstrated by the evidence that carriers of LQTS mutations lacking QT interval prolongation, who therefore escape clinical diagnosis, have a 10 percent risk of major cardiac events by age 40 years whenever left untreated.
In LQTS, disease severity and response to therapy vary according to the genetic mutation involved. There exists a critical need to devise more efficient genetic testing for LQTS.
Carlo Napolitano, of the S. Maugeri Foundation, Pavia, Italy, and colleagues performed genetic screening in patients with LQTS to determine the yield of genetic testing, as well as the type and the prevalence of mutations.
The study involved genetic testing of 430 patients with LQTS and 1,115 family members between June 1996 and June 2004. The researchers confirmed their findings by testing for the identified mutations in a separate cohort of 75 patients.
The researchers identified 235 different mutations, 138 of which were new, in 310 ( 72 percent ) of 430 patients.
" The clinical value of molecular screening is influenced by the percentage of successfully genotyped individuals. Our data show that 70 percent of Romano Ward, a genetic mutation of LQTS, probands can be successfully genotyped by standard methods based on the current knowledge about the molecular substrate of LQTS. This number, obtained in a population of consecutively genotyped patients, is high enough to support the introduction of genotyping into clinical medicine," the authors write.
" We have developed an approach to improve the efficiency of genetic screening for LQTS," the researchers write. " The novel strategy for LQTS genotyping may facilitate the access to genetic testing to a broader group of individuals, such as patients receiving drugs that … prolong QT interval; family members of individuals with idiopathic ventricular fibrillation; and depending on results of further investigation, members of the general population to define the prevalence of known genetic variants of LQTS."
In an accompanying editorial, Elizabeth S. Kaufman, of Metro Health Medical Center and Case Western Reserve University, Cleveland, comments on the study on LQTS.
" Napolitano et al have provided important new information about the yield of genetic testing and about the distribution of mutations, and their proposed efficient genotyping strategy could make genetic testing accessible to more families with LQTS but at the cost of some accuracy. As the authors note, 'the more complete the screening process the higher the accuracy of the results of genetic analysis. … The ideal screening should include the evaluation of the entire coding region of each disease-related gene of each patient. However, this comprehensive approach may be neither possible nor cost-effective' everywhere based on current technology. Novel technologies for rapid and efficient DNA sequencing are on the horizon. Until these technologies are developed further, the medical community will have to decide how much accuracy is reasonable to sacrifice to make genetic testing more accessible."
